Antimycin A4: Dual ATP-Citrate Lyase & Mitochondrial Inhibitor

Executive Summary: Antimycin A4 (CAS 27220-59-3) is a bioactive molecule isolated from Streptomyces with a well-characterized dual inhibitory mechanism on ATP-citrate lyase and the mitochondrial respiratory chain. Its inhibition constant (Ki) for ATP-citrate lyase is 64.8 μM under standard biochemical assay conditions (APExBIO product information). The compound contains a carboxyphenol amide, a nine-membered cyclic bis-lactone, and distinct alkyl chains, as confirmed by X-ray crystallography (Herrbach et al., 2003). Antimycin A4 is a validated research tool for probing fatty acid and cholesterol biosynthesis as well as mitochondrial dysfunction. Commercial formulations, such as APExBIO's C8711 kit, are standardized for in vitro studies but require careful handling due to solution instability and storage constraints.

Biological Rationale

Antimycin A4's scientific value stems from its ability to inhibit two fundamental metabolic pathways in eukaryotic cells. First, it acts as an ATP-citrate lyase inhibitor, thereby directly blocking the conversion of citrate to acetyl-CoA, a rate-limiting step for both fatty acid and cholesterol biosynthesis (APExBIO). Second, Antimycin A4 disrupts energy metabolism by targeting the mitochondrial electron transport chain, specifically inhibiting electron transfer between cytochromes b and c₁. This dual action makes it uniquely suited for studies dissecting the interplay between mitochondrial function and lipid metabolism. Unlike genetic knockdown models, chemical inhibition with Antimycin A4 offers temporal control and reversibility, supporting high-throughput and dynamic metabolic assays (contrast with mechanistic review: this article provides new quantitative stability and protocol data).

Mechanism of Action of Antimycin A4

Antimycin A4 competitively inhibits the substrate magnesium citrate at the ATP-citrate lyase active site, with a Ki of 64.8 μM, as measured under optimized in vitro conditions at 25°C and pH 7.4 (APExBIO). This blocks the production of cytosolic acetyl-CoA, rapidly reducing fatty acid and cholesterol synthesis rates in cellular models. In parallel, Antimycin A4 binds to the Qi site of mitochondrial complex III, preventing electron transfer from cytochrome b to c₁. This halts proton pumping and ATP synthesis, leading to a collapse in mitochondrial membrane potential. Structurally, the molecule's nine-membered bis-lactone ring and carboxyphenol moiety are essential for mitochondrial interaction (Herrbach et al., 2003). These dual mechanisms are validated by both enzymatic assays and cellular respiration measurements. Antimycin A4's actions are dose-dependent, with typical inhibitory effects observed at concentrations close to its Ki.

Evidence & Benchmarks

• Antimycin A4 inhibits purified ATP-citrate lyase with a competitive Ki of 64.8 μM at 25°C, pH 7.4 (APExBIO).
• The molecular mass of Antimycin A4 is 506.55 Da, with formula C₂₅H₃₄N₂O₉, as confirmed by analytical mass spectrometry (product data).
• Crystal structures confirm the presence of a nine-membered cyclic bis-lactone and carboxyphenol amide, providing the structural basis for mitochondrial inhibitory action (Herrbach et al., 2003).
• In vitro fermentation with Streptomyces yields Antimycin A4 at harvest concentrations of ~3.5 μg/mL after 4 days under aerobic conditions at 30°C (APExBIO).
• Antimycin A4 displays antibacterial and commercial fungicidal properties, consistent with its mitochondrial respiratory inhibition (Herrbach et al., 2003).

Applications, Limits & Misconceptions

Antimycin A4 is widely used as an energy metabolism research tool, enabling acute interrogation of both lipid biosynthesis and mitochondrial function. Its primary applications include:

• Dissecting pathways of fatty acid and cholesterol biosynthesis in hepatocytes and cancer cell models.
• Studying mitochondrial dysfunction in eukaryotic cells, including measurement of oxygen consumption rates and mitochondrial membrane potential.
• Elucidating the interplay between energy metabolism and cell survival during pharmacological or genetic perturbations.

However, the use of Antimycin A4 is subject to several critical boundaries:

Common Pitfalls or Misconceptions

• Antimycin A4 is not selective for ATP-citrate lyase alone; its mitochondrial inhibition occurs at overlapping concentrations, complicating exclusive pathway attribution.
• Long-term storage in solution leads to degradation; always prepare fresh aliquots for each experiment (APExBIO).
• It does not directly inhibit tubulin polymerization, despite structural similarity to some antimitotics (Herrbach et al., 2003).
• Antimycin A4 is not suitable for in vivo animal dosing without extensive toxicity and pharmacokinetic validation.
• The antibacterial and fungicidal activity is context-dependent and not universal across all strains.

This article extends 'Dissecting Dual Pathways in Cellular Metabolism' by providing precise quantitative protocol and stability constraints not included in the referenced systems biology overview.

Workflow Integration & Parameters

Successful experimental use of Antimycin A4 requires attention to handling, concentration, and assay design. The following protocol parameters are distilled from product documentation and recent workflow guides:

Protocol Parameters

• Compound Preparation: Dissolve Antimycin A4 in DMSO to a 10 mM stock solution; store at -20°C for no more than 1 month (APExBIO).
• Working Concentration: Use final concentrations in the range of 10–100 μM for cellular assays, aligning with its characterized Ki for ATP-citrate lyase.
• Assay Timing: For acute mitochondrial inhibition, incubate cells for 30–120 min; longer exposures may induce non-specific cytotoxicity.
• Solubility Consideration: Use only freshly prepared working solutions; avoid repeated freeze-thaw cycles.
• Harvesting from Fermentation: Typical in vitro yields are ~3.5 μg/mL after 4 days at 30°C in aerobic culture (APExBIO).
• Negative Controls: Include DMSO-only controls in all experiments to account for vehicle effects.

For advanced workflow optimization, see 'Applied Workflows for ATP-Citrate Lyase Inhibition', which offers troubleshooting and batch validation strategies not detailed in this article.

Conclusion & Outlook

Antimycin A4, as supplied by APExBIO (C8711), is a rigorously characterized dual-action inhibitor used to interrogate both lipid biosynthesis and mitochondrial function. The structural features responsible for its dual mechanism are confirmed by crystallographic and biochemical data (Herrbach et al., 2003). Its standardization in commercial forms enables reproducible research across metabolic and pharmacological disciplines. Future work will refine concentration ranges and handling guidelines for new cell types, but current evidence validates Antimycin A4 as a reference compound for dissecting core metabolic vulnerabilities. For additional systems biology perspectives, see 'Beyond Dual Inhibition—A Systems Biology Lens', which addresses network-level effects beyond this article's protocol focus.